The group's research focuses on the field of cancer therapy and diagnosis. Work focuses on finding molecular markers that enable cancer to be diagnosed in its early stages, where current therapies are most effective, and which ones can also be used for improving tumour prognoses and follow-ups. It also centres on the study of glycoenzymes involved in adhesion and metastasis processes, for possible treatment against their effects.
- Tumour markers: anomalous glycosilation of various seric proteins as possible carcinoma tumour markers.Presently focused on pancreatic and prostate carcinomas, in particular the anomalous glycosilation of over-expressed or new-expressed seric glycoproteins in pancreatic cancer and of PSAs (prostate-specific antigens). Extensible to other glycoproteins (Proteomics and Glycomics).
- Molecular mechanisms responsible for changes in glycosylation in tumoursStudies of the expression of glycosyltransferase responsible for the biosynthesis of carbohydrate antigens associated with tumours, determination of their implication in different stages of tumour progression and of the factors that regulate its expression.
- Directed therapy against specific glycosyltransferase: screening of drugs in 3D models and live validation using drug-response biomarkers